Fig. 5: Synthesis of studies for fluoxetine treatment effects.
From: Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses
A Individual comparisons used in meta-analysis. B Number of genes differentially expressed (left) and pathways enriched (right), vs. number of samples per group in each of the 55 comparisons of fluoxetine treated vs. control samples (q < 0.05). C Pathways identified as significantly enriched (q < 0.05) across the 55 comparisons by the three meta-analysis methods. D Percentage of pathways significantly affected by fluoxetine treatment from each of the Reactome categories (“Top Level”) or KEGG Database. E Heatmap of Normalized Enrichment Score (NES) across comparisons for pathways identified as enriched in any comparison (Fisher’s q < 0.05). Positive NES indicates increased expression with fluoxetine treatment. F Density plot showing distribution of Vote Sums across pathways, colored by meta-analysis result. G q-value by Max-P, and Vote Sums for pathways identified as significant across the 55 comparisons of treated vs. untreated (q < 0.05 by Max-P). * indicates pathways also enriched by Freq50 (p < 0.05 in greater than half of comparisons). H Network diagram showing similarity between pathways, with labels provided in G. Pathways sharing more genes are plotted closer together.
